- Two neuraminidase inhibitors, zanamivir and oseltamivir, are well-tolerated and reduce the likelihood of contracting influenza in both healthy individuals and those who are at risk for developing complications.
- There is insufficient evidence to conclude that neuraminidase inhibitors reduce complications, hospitalization and death from laboratory-confirmed illness.
- Differences between amantadine, zanamivir and oseltamivir exist but the relative contributions of these differences to their overall effectiveness are difficult to assess due to a lack of comparative trials.